US OptionsDetailed Quotes
LFCR241220P7500
- 1.00
- 0.000.00%
15min DelayClose Nov 25 16:00 ET
0.00High0.00Low
1.00Open1.00Pre Close0 Volume242 Open Interest7.50Strike Price0.00Turnover59.87%IV12.87%PremiumDec 20, 2024Expiry Date0.04Intrinsic Value100Multiplier25DDays to Expiry0.96Extrinsic Value100Contract SizeAmericanOptions Type-0.4760Delta0.3430Gamma15.71Leverage Ratio-0.0090Theta-0.0024Rho-7.48Eff Leverage0.0077Vega
Lifecore Biomedical Stock Discussion
Dow Jones· 1 min ago
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
Lifecore Biomedical (NASDAQ: LFCR) reported its fiscal year 2024 results, showing strong revenue growth of 24.2% to $128.3 million.
The company's CDMO business grew 27%, while its HA raw material manufacturing increased 18%.
Gross profit rose 49.5% to $41.9 million, with margin expanding to 32.6%.
Key highlights include:
Net income from con...
$American International Group (AIG.US)$ $Bioventus (BVS.US)$ $CohBar (CWBR.US)$ $HeartCore Enterprises (HTCR.US)$ $Intuit (INTU.US)$ $Lifecore Biomedical (LFCR.US)$ $Lipocine (LPCN.US)$ $Microbot Medical (MBOT.US)$ $Ocean Biomedical (OCEA.US)$ $Palo Alto Networks (PANW.US)$ $RenaissanceRe Holdings (RNR.US)$ $SunCar technology (SDA.US)$ $Sysco Corp (SYY.US)$ $TEMA MONOPOLIES AND OLIGOPOLIES ETF (TOLL.US)$ $Western Digital (WDC.US)$
150M$ refinancing deal
No comment yet